Congenital Adrenal Hyperplasia Market Set to Experience Unprecedented Growth During the Forecast Period (2023-32) - Estimates DelveInsight | Neurocrine Biosciences, Diurnal Limited, Spruce Biosciences, Adrenas, Millendo Therapeutics, Crinetics

Congenital Adrenal Hyperplasia Market size in the seven major markets was approximately USD 21 million in 2021 and it is expected to grow by 2032. As per DelveInsight, the Congenital Adrenal Hyperplasia Market is anticipated to evolve immensely in the coming years owing to the increasing prevalent population of CAH patients in the 7MM and the launch of pipeline therapies in the market.

The pipeline for CAH is robust with companies working towards new approaches for therapy development. Novel treatment options aim to reduce glucocorticoid exposure, improve excess hormone control (e.g. Tildacerfont), and mimic physiological hormone patterns (e.g. Chronocort).

DelveInsight's "Congenital Adrenal Hyperplasia Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Congenital Adrenal Hyperplasia Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Congenital Adrenal Hyperplasia therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Congenital Adrenal Hyperplasia treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Congenital Adrenal Hyperplasia: An Overview
Congenital adrenal hyperplasia (CAH) is a group of rare inherited autosomal recessive disorders characterized by a deficiency of one of the enzymes needed to make specific hormones. CAH affects the adrenal glands located at the top of each kidney.

The most common cause of CAH is the absence of the enzyme 21-hydroxylase. Different mutations in the gene are responsible for 21-hydroxylase, which results in different levels of the enzyme, producing a spectrum of effects. 21-hydroxylase deficiency is broken down further into two subcategories: Classical CAH, which can be subdivided into the Salt-Losing (SL) form or the Simple-Virilizing (SV) form, and Non-Classical CAH. Classical CAH is by far the more severe form and can result in adrenal crisis and death if not detected and treated. Non-classical CAH is milder, and may or may not present symptoms

Treatment of CAH varies greatly depending on the type and severity. Upon confirming the diagnosis of classical salt-losing or simple virilizing 21-OHD, glucocorticoid and mineralocorticoid hormone replacement therapies need to be initiated. Although patients with simple virilizing 21-OHD are not overt salt losers, they may benefit from mineralocorticoid replacement therapy. Currently, the approved therapies for CAH are Alkindi and Efmody both developed by Diurnal Group plc. Other treatment options include Glucocorticoid therapy (Prednisone, Dexamethasone), Mineralocorticoid therapy (Fludrocortisone), and surgical therapy.

Congenital Adrenal Hyperplasia Market Key Facts
• The Congenital Adrenal Hyperplasia diagnosed prevalence in the 7MM countries was estimated to be close to 73,000 cases in 2021.
• According to the National Organization for Rare Disorders (NORD), (n.d.), the most common form of CAH affects approximately 1/10,000-1/15,000 people in the United States and Europe.
• According to the results of a study by Shmouni et al, (2017), nonclassic CAH carriership was found in 9.5% of Caucasians. The estimated prevalence of nonclassic CAH in Caucasians was in 200.
• According to a study by Witchel et al., (2017), the incidence of the classic forms is reported to be in the range from 1:5000 to 1:15,000 and varies among ethnic/racial backgrounds. Additionally, the prevalence of 21-OHD is lower among African-Americans than Caucasians in the United States.

Discover How Congenital Adrenal Hyperplasia Market Will Grow by 2032:
https://www.delveinsight.com/report-store/congenital-adrenal-hyperplasia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Congenital Adrenal Hyperplasia Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Congenital Adrenal Hyperplasia therapies in the market. It also provides a detailed assessment of the Congenital Adrenal Hyperplasia market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the market trend for each marketed Congenital Adrenal Hyperplasia drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Congenital Adrenal Hyperplasia Epidemiology
The epidemiology section covers detailed insights into the historical, and current Congenital Adrenal Hyperplasia patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Congenital Adrenal Hyperplasia Epidemiology Segmented as -
• Total Prevalent Cases of Congenital Adrenal Hyperplasia in the 7MM [2019-2032]
• Diagnosed Prevalent Cases of Classic and Non-classic Congenital Adrenal Hyperplasia in the 7MM [2019-2032]
• Total Diagnosed Cases of Congenital Adrenal Hyperplasia in the 7MM [2019-2032]

Get Key Insights Into the Evolving Congenital Adrenal Hyperplasia Epidemiology Trends @
https://www.delveinsight.com/report-store/congenital-adrenal-hyperplasia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Congenital Adrenal Hyperplasia Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Congenital Adrenal Hyperplasia market or expected to be launched during the study period. The analysis covers the market share by Congenital Adrenal Hyperplasia drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Congenital Adrenal Hyperplasia Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities @
https://www.delveinsight.com/sample-request/congenital-adrenal-hyperplasia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Congenital Adrenal Hyperplasia Therapeutics Assessment
The dynamics of the Congenital Adrenal Hyperplasia market are anticipated to change in the coming years owing to the rising awareness of the disease, expansion of therapies into new applications such as pediatric use and better approaches to therapy development across the world. Major pipeline therapies under development for the treatment of CAH are Tildacerfont (Spruce Biosciences), Crinecerfont (NBI-74788) (Neurocrine Biosciences), and others. Currently, Diurnal Group plc is leading the therapeutics market with its Congenital Adrenal Hyperplasia drug candidates in the most advanced stage of clinical development.

Leading Companies in the Congenital Adrenal Hyperplasia Therapeutics Market Include
• Neurocrine Biosciences
• Diurnal Limited
• Spruce Biosciences
• Adrenas Therapeutics
• Millendo Therapeutics
• Crinetics Pharmaceuticals
And Many Others

Emerging and Marketed Congenital Adrenal Hyperplasia Therapies Covered in the Report Include
• Chronocort: Diurnal Group plc
• Crinecerfont: Neurocrine Biosciences
• Tildacerfont: Spruce Biosciences
• AAV BBP-631: Adrenas Therapeutics
And Many More

Learn More About the Emerging Therapies & Key Companies in the Congenital Adrenal Hyperplasia Therapeutics Market:
https://www.delveinsight.com/sample-request/congenital-adrenal-hyperplasia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Congenital Adrenal Hyperplasia Competitive Intelligence Analysis
4. Congenital Adrenal Hyperplasia Market Overview at a Glance
5. Congenital Adrenal Hyperplasia Background and Overview
6. Congenital Adrenal Hyperplasia Patient Journey
7. Congenital Adrenal Hyperplasia Epidemiology and Patient Population
8. Congenital Adrenal Hyperplasia Treatment Algorithm, Current Treatment, and Medical Practices
9. Congenital Adrenal Hyperplasia Unmet Needs
10. Key Endpoints of Congenital Adrenal Hyperplasia Treatment
11. Congenital Adrenal Hyperplasia Marketed Products
12. Congenital Adrenal Hyperplasia Emerging Therapies
13. Congenital Adrenal Hyperplasia Seven Major Market Analysis
14. Attribute Analysis
15. Congenital Adrenal Hyperplasia Market Outlook (7 major markets)
16. Congenital Adrenal Hyperplasia Access and Reimbursement Overview
17. KOL Views on the Congenital Adrenal Hyperplasia Market.
18. Congenital Adrenal Hyperplasia Market Drivers
19. Congenital Adrenal Hyperplasia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/congenital-adrenal-hyperplasia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

-------------------------------------------- xx --------------------------------------------
Other Trending Healthcare Reports by DelveInsight
Dementia with Diabetes Market
https://www.delveinsight.com/report-store/dementia-with-diabetes-market-forecast

Indolent Lymphoma Market
https://www.delveinsight.com/report-store/indolent-lymphoma-market

Liver Angiosarcoma Market
https://www.delveinsight.com/report-store/liver-angiosarcoma-market

Venous Stenosis Market
https://www.delveinsight.com/report-store/venous-stenosis-market

Bronchial Hyperreactivity Market
https://www.delveinsight.com/report-store/bronchial-hyperreactivity-market

Pegfilgrastim Biosimilar
https://www.delveinsight.com/report-store/pegfilgrastim-biosimilar-insight

Cytokine Release Syndrome Market
https://www.delveinsight.com/report-store/cytokine-release-syndrome-market

Primary Progressive Multiple Sclerosis (PPMS) Market
https://www.delveinsight.com/report-store/primary-progressive-multiple-sclerosis-ppms-market

Singapore Healthcare Outlook
https://www.delveinsight.com/report-store/singapore-healthcare-outlook-report

Hematuria Market
https://www.delveinsight.com/report-store/hematuria-market

Varicose Ulcer Market
https://www.delveinsight.com/report-store/varicose-ulcer-market

Anaplastic Astrocytoma Market
https://www.delveinsight.com/report-store/anaplastic-astrocytoma-market

Lymphoedema Market
https://www.delveinsight.com/report-store/lymphoedema-market

Morquio Syndrome Market
https://www.delveinsight.com/report-store/morquio-syndrome-market

Nasopharyngeal Carcinoma Market
https://www.delveinsight.com/report-store/nasopharyngeal-carcinoma-market

CART-related Neurotoxicity (NT) Market
https://www.delveinsight.com/report-store/cart-related-neurotoxicity-nt-market

Total Knee Arthroplasty Market
https://www.delveinsight.com/report-store/total-knee-arthroplasty-market

Cushing's Syndrome Market
https://www.delveinsight.com/report-store/cushings-syndrome-market

Tumor Ablation Market
https://www.delveinsight.com/report-store/tumor-ablation-market

Diabetes Market
https://www.delveinsight.com/report-store/diabetes-market

Autism Spectrum Disorder Market
https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Market
https://www.delveinsight.com/report-store/blastic-plasmacytoid-dendritic-cell-neoplasm-bpdcn-market

Urinary Incontinence Market
https://www.delveinsight.com/report-store/urinary-incontinence-market

Seborrhoeic Dermatitis Market Substance (Drug) Abuse Market
https://www.delveinsight.com/report-store/substance-drug-abuse-market

Artificial Cornea and Corneal Implant Market
https://www.delveinsight.com/report-store/artificial-cornea-and-corneal-implant-market

Prosthetic Heart Valve Market
https://www.delveinsight.com/report-store/prosthetic-heart-valve-market

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.